Showing results (221-230 of 288) with videos related to
Sort By:
Pageof 29
International Journal of Cancer|November 27, 2012
Human papillomavirus, smoking status and outcomes in tonsillar squamous cell carcinomaAngela M Hong, Andrew Martin, Mark Chatfield, et al.Journal for Immunotherapy of Cancer|August 11, 2025
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumorsMichele Maio, Victor Moreno, Juan Martin-Liberal, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2016
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT InhibitionGeorge Au-Yeung, Franziska Lang, Walid J Azar, et al.Frontiers in Oncology|November 16, 2016
Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)Jérôme Fayette, Lori Wirth, Cristina Oprean, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2025
Randomized Phase Ib Clinical Trial of DB-020 Intratympanic Injections to Reduce High-Dose Cisplatin OtotoxicityBenedict J Panizza, Stephen John O'Leary, Christopher David Hart, et al.International Journal of Cancer|January 18, 2020
Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?Liam Masterson, James Howard, Jazmina Gonzalez-Cruz, et al.Cancer Research|May 19, 2005
An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown originRichard W Tothill, Adam Kowalczyk, Danny Rischin, et al.Cancer Research|August 23, 2015
Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated ProdrugsFrancis W Hunter, Richard J Young, Zvi Shalev, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2003
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2023
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non-Small-Cell Lung CancerMasahiro Fukuoka, Seiji Yano, Giuseppe Giaccone, et al.Pageof 29